Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone610-640-4202
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$52.78 million
Profitability
Miscellaneous
Employees191
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable
Neuronetics (NASDAQ:STIM) Frequently Asked Questions
What is Neuronetics' stock symbol?
Neuronetics trades on the NASDAQ under the ticker symbol "STIM."
How were Neuronetics' earnings last quarter?
Neuronetics Inc (NASDAQ:STIM) posted its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.05. The business earned $12.73 million during the quarter, compared to analysts' expectations of $12.72 million. Neuronetics had a negative return on equity of 1,385.60% and a negative net margin of 47.21%. View Neuronetics' Earnings History.
When is Neuronetics' next earnings date?
What guidance has Neuronetics issued on next quarter's earnings?
Neuronetics updated its FY 2019 earnings guidance on Tuesday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $62.5-64.5 million, compared to the consensus revenue estimate of $63.28 million.Neuronetics also updated its Q2 2019 guidance to EPS.
What price target have analysts set for STIM?
5 analysts have issued twelve-month price targets for Neuronetics' shares. Their predictions range from $25.00 to $40.00. On average, they expect Neuronetics' stock price to reach $32.25 in the next year. This suggests a possible upside of 179.0% from the stock's current price. View Analyst Price Targets for Neuronetics.
What is the consensus analysts' recommendation for Neuronetics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neuronetics.
What are Wall Street analysts saying about Neuronetics stock?
Here are some recent quotes from research analysts about Neuronetics stock:
- 1. According to Zacks Investment Research, "Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics, Inc. is based in Malvern, United States. " (5/8/2019)
- 2. BTIG Research analysts commented, "$25 PT Neuronetics reported 4Q18 results with both capital sales and treatment revenue surpassing our forecast. Ending BDM count was in-line with expectations, implying rep productivity is ahead of planned (mgmt confirmed the same). Looking ahead to FY19, top-line guidance brackets current Street estimates. Mgmt is assuming more rep hires than the Street, driving up the operating expense outlook. On underlying assumptions, mgmt appears to be basing forecasts on historical productivity metrics instead of more recent encouraging trends likely creating upside. Additionally, the company does not appear to be aggressively signaling gross margin expansion though we still feel a greater mix of higher-margin consumable sales should push this metric higher." (3/6/2019)
Has Neuronetics been receiving favorable news coverage?
Press coverage about STIM stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neuronetics earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Neuronetics.
Who are some of Neuronetics' key competitors?
Some companies that are related to Neuronetics include Intersect ENT (XENT), AngioDynamics (ANGO), Cerus (CERS), Orthopediatrics (KIDS), Anika Therapeutics (ANIK), SurModics (SRDX), MiMedx Group (MDXG), OraSure Technologies (OSUR), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), SI-Bone (SIBN), GenMark Diagnostics (GNMK), Vapotherm (VAPO), Accuray (ARAY) and Utah Medical Products (UTMD).
What other stocks do shareholders of Neuronetics own?
Who are Neuronetics' key executives?
Neuronetics' management team includes the folowing people:
- Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)
- Mr. Peter L. Donato, CFO, VP & Corp. Sec. (Age 49)
- Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)
- Ms. Cassie Hallberg, VP of Marketing
- Mr. Daniel Guthrie, Chief Commercial Officer & VP (Age 42)
When did Neuronetics IPO?
(STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.
Who are Neuronetics' major shareholders?
Neuronetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.05%), Polaris Venture Management Co. V L.L.C. (4.06%), Wells Fargo & Company MN (1.80%), Wasatch Advisors Inc. (1.72%), Pier Capital LLC (1.70%) and FMR LLC (1.20%). Company insiders that own Neuronetics stock include Christopher Thatcher, Daniel Guthrie, Peter Donato and Wilfred E Jaeger. View Institutional Ownership Trends for Neuronetics.
Which institutional investors are selling Neuronetics stock?
STIM stock was sold by a variety of institutional investors in the last quarter, including Polaris Venture Management Co. V L.L.C., Wells Fargo & Company MN, Morgan Stanley, Frontier Capital Management Co. LLC, FMR LLC and Blair William & Co. IL. Company insiders that have sold Neuronetics company stock in the last year include Christopher Thatcher, Daniel Guthrie and Peter Donato. View Insider Buying and Selling for Neuronetics.
Which institutional investors are buying Neuronetics stock?
STIM stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Wasatch Advisors Inc., Northern Trust Corp, JPMorgan Chase & Co., Granite Investment Partners LLC, Pier Capital LLC, Alambic Investment Management L.P. and Charles Schwab Investment Management Inc.. Company insiders that have bought Neuronetics stock in the last two years include Daniel Guthrie and Wilfred E Jaeger. View Insider Buying and Selling for Neuronetics.
How do I buy shares of Neuronetics?
Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neuronetics' stock price today?
One share of STIM stock can currently be purchased for approximately $11.56.
How big of a company is Neuronetics?
Neuronetics has a market capitalization of $211.66 million and generates $52.78 million in revenue each year. The company earns $-24,100,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Neuronetics employs 191 workers across the globe.View Additional Information About Neuronetics.
What is Neuronetics' official website?
How can I contact Neuronetics?
Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]
MarketBeat Community Rating for Neuronetics (NASDAQ STIM)
MarketBeat's community ratings are surveys of what our community members think about Neuronetics and other stocks. Vote "Outperform" if you believe STIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
